Gennova Biopharmaceuticals’ Covid-19 jab HGCO19, based on the mRNA technology platform, will be a lyophilized vaccine or one that is based on freeze-drying. This should help store the vaccine at much higher temperatures than the stringent sub-zero temperatures required to maintain a stable cold chain for other mRNA vaccines globally.

The lyophilized vaccine will come in a powder form and it will be mixed with diluents before administration.
https://www.business-standard.com/article/current-affairs/gennova-s...